Welcome to our dedicated page for Neurocrine Biosciences news (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences stock.
Neurocrine Biosciences Inc (NBIX) is a leading neuroscience-focused biopharmaceutical company developing innovative therapies for complex neurological, endocrine, and neuropsychiatric disorders. This comprehensive news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives driving the company's mission to address unmet medical needs.
Stay informed with verified updates spanning FDA decisions, clinical trial results, research collaborations, and market expansion efforts. Our curated news collection covers essential developments including movement disorder therapies like Ingrezza® for tardive dyskinesia, endocrine disorder treatments, and emerging pipeline candidates in neuropsychiatry.
Key focus areas include updates on late-stage clinical programs, partnership announcements with academic institutions, and analyses of therapeutic innovations targeting conditions from Huntington's disease chorea to congenital adrenal hyperplasia. All content is rigorously sourced to ensure accuracy and relevance for both professional investors and medical stakeholders.
Bookmark this page for centralized access to Neurocrine Biosciences' latest scientific advancements, financial disclosures, and treatment development progress. Check regularly for objective reporting on one of biopharma's most innovative neuroscience-focused enterprises.
Neurocrine Biosciences (Nasdaq: NBIX) will announce its third quarter 2021 financial results on November 1, 2021, after market close. The company will then host a conference call and webcast at 1:30 p.m. PT to discuss the results and provide updates. Participants can join via phone or through their website. Neurocrine specializes in treatments for neurological and endocrine disorders, with a diverse product portfolio.
Neurocrine Biosciences (Nasdaq: NBIX) will present new data on its movement disorder treatments at the MDS Virtual Congress 2021 from September 17–22. Key findings include a post hoc analysis from the KINECT 4 Phase 3 study, showing significant reductions in tardive dyskinesia (TD) symptoms with once-daily INGREZZA (valbenazine). Additionally, pooled data from BIPARK-1 and BIPARK-2 studies will evaluate ONGENTYS (opicapone) effects on sleep patterns in Parkinson's patients. Neurocrine aims to enhance understanding of TD and Parkinson's disease management.
Neurocrine Biosciences (Nasdaq: NBIX) announced participation in two virtual investor conferences. CEO Kevin Gorman will present at the Morgan Stanley 19th Annual Healthcare Conference on Sept. 13, 2021, at 10:15 a.m. ET. CFO Matt Abernethy and CMO Eiry Roberts will speak at the Baird 2021 Global Healthcare Conference on Sept. 15, 2021, at 10:50 a.m. ET. Live presentations can be accessed on the company's website, with replays archived for one month. Neurocrine focuses on therapies for neurological and psychiatric disorders.
Neurocrine Biosciences (Nasdaq: NBIX) has completed patient enrollment for the Phase 3 KINECT-HD study, investigating the efficacy and safety of valbenazine for treating chorea in Huntington disease. The top-line results are expected by the end of 2021. This study offers hope for the approximately 30,000 U.S. adults affected by Huntington disease, whose current treatment options carry significant risks. Following KINECT-HD, participants can join KINECT-HD2, an open-label extension study to evaluate long-term safety.
Neurocrine Biosciences (NBIX) reported Q2 2021 financial results, with total revenues of $288.9 million, down from $302.4 million in Q2 2020. Product sales for INGREZZA were $266.8 million, a slight decline from $267.6 million year-over-year. GAAP net income fell to $42.3 million ($0.43 per share) compared to $79.6 million ($0.81 per share) in Q2 2020. Increased R&D and SG&A expenses significantly impacted earnings. Notably, the company is advancing its R&D pipeline with plans for nine mid-to-late-stage trials in 2021.
Neurocrine Biosciences (Nasdaq: NBIX) will announce its second quarter 2021 financial results on August 3, 2021, after Nasdaq market closure. A conference call and webcast will follow at 1:30 p.m. PT to discuss the results and company updates. Participants can join the call by dialing 866-952-8559 (US) or 785-424-1743 (International) using conference ID: NBIX. The webcast will be available on the Neurocrine website and archived for one month.
Neurocrine Biosciences (Nasdaq: NBIX) announced its participation in the William Blair Biotech Focus Conference on July 15, 2021, where Kyle Gano, Chief Business Development and Strategy Officer, will take part in a panel discussion focused on neuropsychology. The live presentation is scheduled for 12:00 p.m. Eastern Time and will be webcast via the company's website. A replay will be available shortly after the event and archived for one month. Neurocrine specializes in developing treatments for neurological and psychiatric disorders.
Neurocrine Biosciences (Nasdaq: NBIX) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 1:20 p.m. ET. CEO Kevin Gorman will lead the presentation. Attendees can access the live webcast on the company's website, with a replay available about an hour after the event, archived for one month. Neurocrine focuses on developing treatments for neurological and endocrine disorders, with a portfolio that includes FDA-approved therapies for tardive dyskinesia, Parkinson's disease, and more.
Neurocrine Biosciences (Nasdaq: NBIX) will present at the 2021 RBC Capital Markets Healthcare Conference on May 18, 2021 at 10:55 a.m. Eastern Time. The presentation will feature CFO Matt Abernethy and CMO Eiry Roberts. Interested parties can access the live webcast on the company's website, with a replay available afterward for one month. Neurocrine focuses on innovative treatments for neurological and psychiatric disorders, with a portfolio that includes FDA-approved therapies for tardive dyskinesia and Parkinson's disease.
Neurocrine Biosciences (NBIX) reported $236.6 million in total revenues for Q1 2021, slightly down from $237.1 million in Q1 2020. Product sales from INGREZZA were $231 million. GAAP net income decreased to $32.1 million, with diluted earnings per share at $0.33 compared to $0.39 in the previous year. The company revised its full-year expense guidance to $855-$905 million for GAAP R&D and SG&A. Despite lower refill rates attributed to seasonal payor dynamics and COVID disruptions, new patient starts for INGREZZA improved late in the quarter, signaling a potential recovery.
